Published in MAbs on March 26, 2014
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood (2015) 1.57
Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol (2015) 1.17
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J Hematol Oncol (2015) 1.14
NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer (2015) 1.04
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs (2015) 0.97
Second- and third-generation ALK inhibitors for non-small cell lung cancer. J Hematol Oncol (2016) 0.96
AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. J Hematol Oncol (2015) 0.94
The making of bispecific antibodies. MAbs (2017) 0.84
A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy. Oncotarget (2014) 0.84
Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site. Immunol Rev (2016) 0.82
Improving natural killer cell cancer immunotherapy. Curr Opin Organ Transplant (2015) 0.80
Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol (2016) 0.80
Bispecific antibodies in cancer immunotherapy. Hum Vaccin Immunother (2016) 0.80
Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside. Oncotarget (2016) 0.79
Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG. Exp Hematol Oncol (2016) 0.78
Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies. Int J Mol Sci (2016) 0.77
A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy. PLoS One (2015) 0.76
Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds. Front Immunol (2017) 0.75
Harnessing NK Cell Memory for Cancer Immunotherapy. Trends Immunol (2016) 0.75
Detection of a phosphorylated glycine-serine linker in an IgG-based fusion protein. MAbs (2016) 0.75
Acute myeloid leukemia targets for bispecific antibodies. Blood Cancer J (2017) 0.75
The biology of human natural killer-cell subsets. Trends Immunol (2001) 10.10
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood (2002) 8.76
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol (2008) 6.90
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol (2003) 6.77
Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature (2001) 4.76
Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A (2006) 3.54
Biology and clinical relevance of human natural killer cells. Blood (1990) 3.50
The biology of Hodgkin's lymphoma. Nat Rev Cancer (2008) 3.31
Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today (1993) 3.28
Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood (1997) 3.19
Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood (2003) 2.47
Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci U S A (1999) 1.71
Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res (2001) 1.62
Isolation of whole mononuclear cells from peripheral blood and cord blood. Curr Protoc Immunol (2009) 1.48
Biallelic neutrophil Na-antigen system is associated with a polymorphism on the phospho-inositol-linked Fc gamma receptor III (CD16). Blood (1990) 1.22
Characterization of polymorphic forms of Fc receptor III on human neutrophils. J Clin Invest (1989) 1.21
Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther (2013) 1.16
Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease. Cancer Res (1990) 1.13
Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol (1999) 1.11
The binding epitopes of human CD16 (Fc gamma RIII) monoclonal antibodies. Implications for ligand binding. J Immunol (1996) 1.08
Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol (2001) 1.00
Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Protein Eng Des Sel (2004) 0.98
Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood (1997) 0.97
Molecular heterogeneity of murine mast cell Fc gamma receptors. J Immunol (1990) 0.96
Immunosuppressive properties of anti-CD3 single-chain Fv and diabody. J Immunol Methods (2004) 0.93
A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors. Blood (1999) 0.91
Immunotherapeutic perspective for bispecific antibodies. Immunol Today (2000) 0.91
Functional humanization of an anti-CD30 Fab fragment for the immunotherapy of Hodgkin's lymphoma using an in vitro evolution approach. Protein Eng Des Sel (2005) 0.86
A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo. Int J Cancer (1993) 0.86
Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. J Immunol (2002) 0.85
Binding affinity and inhibitory properties of a single-chain anti-T cell receptor antibody. J Biol Chem (1993) 0.81
CD30 is involved in inhibition of T-cell proliferation by Hodgkin's Reed-Sternberg cells. Cancer Res (2004) 0.80